SpringWorks Therapeutics, Inc. (SWTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 25.49 |
| Open | 25.61 |
| Bid | 25.56 x 800 |
| Ask | 26.99 x 800 |
| Day's Range | 25.28 - 26.32 |
| 52 Week Range | 13.60 - 61.62 |
| Volume | |
| Avg. Volume | 726,183 |
| Market Cap | 1.606B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Drug Application Under Review by the FDA with PDUFA Action Date of August 27, 2023 – STAMFORD, Conn., March 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from the
- GlobeNewswire
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media
- GlobeNewswire
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Topline Data from Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas Expected in the Second Half of 2023 – – Dosed First Patient in Phase 1/2a Combination Study of BGB-3245 and Mirdametinib – – Expanded Intellectual Property Portfolio, Strengthening Protection for Nirogacestat into
